The US Oncology Network now has more than 2400 providers who treat over 1.4 million patients annually at approximately 600 sites of care in 30 states.
The US Oncology Network announced November 13, 2023, that Nashville Oncology Associates (NOA) has joined The Network, effective October 1, 2023.
“We are eager to have Nashville Oncology Associates join us on our mission to increase access to convenient, high-quality cancer care in the Nashville region,” Jason Hammonds, president, The US Oncology Network, said in a statement. “As we welcome these highly skilled cancer specialists into The Network, we extend our reach of comprehensive community-based services into Tennessee for the first time. Our goal is that our support and resources will help enhance the high-quality care NOA provides to patients in the community.”
NOA offers comprehensive cancer treatment services, treating blood cancers and disorders, as well as bone, breast, lung, reproductive, skin, gastrointestinal, colorectal, and urinary tract cancers, nurturing an atmosphere of trust and compassion. Medical oncologists Karl M. Rogers, MD, the practice president, and Carl R. Willis, MD, offer care with 2 advanced practice providers.
“Joining The Network will provide access to a wealth of operational and clinical resources that will help us continue to deliver superior care while empowering us to remain independent in today’s challenging environment,” Rogers said in the statement.
The US Oncology Network now has more than 2400 providers who treat over 1.4 million patients annually at approximately 600 sites of care in 30 states.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Contributor: The Diabetes Vendor Resource Guide—A Useful Directory for Employers
November 13th 2024Employees living with diabetes often face unique challenges, such as managing blood sugar levels, balancing medication, and preventing complications, all while maintaining their professional responsibilities. This condition can lead to increased absenteeism, reduced productivity, and rising health care costs.
Read More
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More